动脉粥样硬化进展与指南.pptVIP

* IDEAL Results Are Consistent With TNT Results from the IDEAL study1 build upon those demonstrated by TNT.2 In IDEAL, a significant 13% reduction in major CV events was seen with atorvastatin 80 mg versus usual-dose (20 mg to 40 mg) simvastatin. Similar findings were seen in the TNT study, in which a 22% relative risk reduction was demonstrated with atorvastatin 80 mg compared with atorvastatin 10 mg.1,2 References 1. Pedersen TR, Faergeman O, Kastelein JJP, et al, for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA. 2005;294:2437-2445. 2. LaRosa JC, Grundy SM, Waters DD, et al, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435. * IDEAL Results Are Consistent With PROVE IT Results from the IDEAL study demonstrate a significant 16% reduction in any CHD event (composite of major coronary event, revascularization, or hospitalization for unstable angina) even with atorvastatin 80 mg versus usual-dose (20 mg to 40 mg) simvastatin.1 Consistent findings were seen in PROVE IT, which showed a significant 16% risk reduction in a similar composite end point (death, MI, revascularization, unstable angina, or stroke), death, or major CV events with atorvastatin 80 mg compared with pravastatin 40 mg in patients with ACS.2  References 1. Pedersen TR, Faergeman O, Kastelein JJP, et al, for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL Study: a randomized controlled trial. JAMA. 2005;294:2437-2445. 2. Cannon CP, Braunwald E, McCabe CH, et al, for the Pravastatin or At